ArticleFrontiers in immunology2023

Third COVID-19 vaccine dose for people with multiple sclerosis who did not seroconvert following two doses of BBIBP-CorV (Sinopharm) inactivated vaccine: A pilot study on safety and immunogenicity.

Nahad Sedaghat et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.